XXII

22nd Century Group, Inc.

8 filings tracked

consumer staplestobaccoMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMay 7

Net loss from continuing operations widened to $3.0M with a significant drop in revenue.

earnings miss

80%

bullishMay 7

Raised $15.3M via Series B convertible preferred stock to clean up the capital stack.

capital raise

60%

bearishMay 7

Gross loss remained consistent despite revenue drops, indicating a lack of pricing power.

margin compression

70%

bullishMay 7

Interest expense collapsed 98% following the retirement of legacy debt and preferred shares.

debt restructure

50%

bearishMar 26

Gross loss widened to $3.1M in 2025, representing 17.8% of net revenue.

margin compression

70%

bullishMar 26

Fully repaid Senior Secured Credit Facility in September 2025.

debt restructure

60%

neutralMar 26

Issued $16M in Series B Convertible Preferred Stock to fund operations.

capital raise

50%

bullishMar 26

Positioned to benefit from proposed FDA nicotine yield caps of 0.7 mg/g.

regulatory action

80%

Filing History

10-QMay 7, 2026

The Q1 2026 filing reveals a company at a crossroads, attempting to leverage a rare regulatory asset—the FDA's MRTP authorization—while battling systemic financial instability. The successful refinancing of its preferred equity and the drastic reduction in interest expenses provide a temporary reprieve, but the core business model has yet to prove it can generate a positive gross profit. The trade-off for investors is now a binary bet on whether the company can scale its proprietary low-nicotine products before its remaining cash is exhausted by operating losses. Ultimately, the filing highlights a stark contrast between the company's long-term regulatory potential and its immediate fiscal distress. While the balance sheet is cleaner than in previous periods, the 'going concern' warning remains a dominant feature of the report. Investors must weigh the strength of the FDA-backed moat against the reality of a business that is currently selling products at a loss and relying on equity issuances to sustain operations.

10-KMar 26, 2026

The 10-K reveals a company at a critical crossroads, balancing a potentially disruptive product advantage against a deteriorating balance sheet. The strategic pivot toward the VLN® brand and the elimination of high-interest debt are positive steps, but they are overshadowed by a net loss of over $13 million from continuing operations and a critical need for ongoing capital raises. The company is essentially betting its survival on the FDA's final ruling regarding nicotine caps. Investors are left to weigh the possibility of a first-mover monopoly in a new 'low-nicotine' category against the reality of a cash-starved operation with a shrinking revenue base. The successful repayment of the Senior Secured Credit Facility and the Series B offering provide a temporary reprieve, but the path to profitability requires a rapid acceleration of sales and the finalization of favorable federal regulations.